申请人对血小板受体PEAR1进行了长期深入的研究，前期发现PEAR1在血小板黏附活化中发挥了重要的作用，影响血小板聚集和抗血小板药物的药效。近年有报道PEAR1在血管内皮高表达，调控血管内皮细胞损伤修复和血管新生，但PEAR1该能力在各种生理病理状态下如何体现、是否有组织特异性、作用机制尚缺乏研究。本课题首先利用pear1基因敲除小鼠通过后肢缺血、皮肤伤口愈合、口腔溃疡愈合、动脉粥样硬化斑块/心脏新生血管、肝脏原位移植瘤模型实验，明确在不同组织、病理状态下PEAR1调控内皮损伤修复和血管新生的能力差异并进行机理研究；在人体水平，采集下肢动脉闭塞患者病变和正常血管组织、肝细胞癌患者肝癌细胞组织，分析PEAR1及相关基因蛋白表达、mRNA水平、甲基化、PEAR1rs12041331基因型与病变或癌细胞能力的相关性，从动物和人体水平评估PEAR1作为药物新靶点的潜力。

Our previous studies found that PEAR1 plays an important role in platelet adhesion activation, which affects platelet aggregation and antiplatelet drug’s efficacy. Recent years, it has been reported that PEAR1 is highly expressed in vascular endothelium, which can regulate the injury impairing of vascular endothelial cell and angiogenesis. However, how PEAR1 is manifested in various physiological and pathological conditions, whether it is tissue-specific, and the mechanism of its action is still not clear. To identify the ability of PEAR1 in different tissues and pathological conditions and to clarify the mechanism, this study uses Pear1-knockout mice to build hind limb ischemia, skin wound healing, oral ulcer healing, atherosclerotic plaque, cardiac neovascularization, and liver orthotropic transplantation models firstly. Then, we collect the lesions of the lower extremity arterial occlusion, the vascular tissue of the adjacent segment, and the liver cancer cell tissue of the primary liver cancer patient at the human body level. Finally, we detect the patient genome, PEAR1 rs1201331 gene of different tissue cells, compare PEAR1 expression levels between tissue and platelet-rich plasma, and evaluate the potential and application of PEAR1 as a novel drug target from both animal and human levels.